<DOC>
	<DOC>NCT01193582</DOC>
	<brief_summary>A vaccine called Prevenar is already approved for use in China for vaccination of children younger than 6 years old against infections caused by Streptococcus pneumoniae. This study is to measure the amount of antibodies (antibodies help people fight off diseases) Chinese children aged between 121 days and 6 years (72 months) produce when given Prevenar. The study will also provide more data on how safe and well tolerated Prevenar is in Chinese children.</brief_summary>
	<brief_title>A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy Chinese male or female subjects. Between 121 days to less than 72 months of age at the time of entry into the study. Receipt of previous vaccine against Pneumo Previous anaphylactic reaction to any vaccine or part of a vaccine Previous proven invasive Pneumo infection Receipt of investigational drug or device within the proceeding 28 days</criteria>
	<gender>All</gender>
	<minimum_age>121 Days</minimum_age>
	<maximum_age>72 Months</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Prevenar</keyword>
	<keyword>catch-up</keyword>
	<keyword>pneumococcal</keyword>
	<keyword>pneumonia</keyword>
</DOC>